GILD up +1.68% percent Today $GILD High is at 102.42 and the Low 100.82 with current volume of 4,158,585.
Recent News posted below.
Gilead Sciences GILD other info.
http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Stock Market Today: S&P 500 Flexes Muscles After Global Markets Pop
at The Street - 12 mins ago
The S&P 500 shows some muscle on Tuesday, rocketing to a new record high as global markets rally.
URBN: 28.00 (-2.83), AGN: 211.85 (+2.65), HD: 95.67 (-2.36), ACT: 262.30 (+14.36), TERP: 33.33 (+7.49), TJX: 59.92 (-1.62), MDT: 71.77 (+2.58), GILD: 102.06 (+1.62), SUNE: 20.61 (+4.00), HIMX: 6.53 (-0.37), AAPL: 114.72 (+0.73), NOK: 7.99 (+0.32)
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - 1 hr 15 mins ago
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 102.06 (+1.62)
Early Glance: Biotechnology companies
AP - 1 hr 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 102.06 (+1.62), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - 1 hr 48 mins ago
GILD: 102.06 (+1.62)
European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - 1 hr 56 mins ago
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 102.06 (+1.62)
Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - 2 hrs 4 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 102.06 (+1.62)
Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - Tue Nov 18, 7:52AM CST
GILD: 102.06 (+1.62)
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - Tue Nov 18, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.40 (+0.15), GILD: 102.07 (+1.63), HAL: 49.10 (-0.13), AAPL: 114.72 (+0.73), BABA: 111.95 (-2.30), BHI: 65.14 (-0.09)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 102.07 (+1.63), ABBV: 65.89 (+0.85)
Final Glance: Biotechnology companies
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 102.07 (+1.63), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Gilead Sciences Earnings Hindsight: Down 10.0% in Last 20 Days (GILD)
Comtex SmarTrend(R) - Mon Nov 17, 3:00PM CST
When Gilead Sciences (NASDAQ:GILD) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.93 on sales of $6.0 billion. The company actually reported EPS of $1.84 on sales of $6.0 billion, missing EPS estimates by $0.09 and beating revenue estimates by $5.4 million. Since the company's report, shares of Gilead Sciences have fallen from $113.45 to $102.06, representing a loss of 10.0% in the past 20 days.
GILD: 102.07 (+1.63)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 109.00 (+0.70), GILD: 102.07 (+1.63), GERN: 3.09 (+0.11), MRK: 60.04 (+0.58), AZN: 73.66 (+1.16), PFE: 30.68 (+0.36), INCY: 69.60 (-0.10), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.68 (+1.30)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 109.00 (+0.70), GILD: 102.05 (+1.61), GLD: 114.77 (+0.72), ABBV: 65.89 (+0.85), TWTR: 40.23 (-0.24), NVS: 95.68 (+1.30)
Midday Glance: Biotechnology companies
AP - Mon Nov 17, 1:21PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.05 (+1.61), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.26 (+2.84), GILD: 102.06 (+1.62), INCY: 69.60 (-0.10), ALXN: 190.81 (+4.03), CELG: 106.67 (+2.31)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.53 (+0.04), HAS: 56.01 (-0.36), BIIB: 305.26 (+2.84), VRTX: 110.23 (-1.39), HAL: 49.09 (-0.14), M: 61.25 (-0.36), WMT: 83.71 (+0.14), SLB: 95.46 (-0.17), COG: 33.14 (-0.39), GILD: 102.06 (+1.62), EOG: 97.14 (+0.79), ALXN: 190.81 (+4.03), MRO: 31.86 (+0.04), CSCO: 26.69 (+0.22), BHI: 65.12 (-0.11)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 109.00 (+0.70), GILD: 102.06 (+1.62), ABBV: 65.89 (+0.85), CELG: 106.67 (+2.31)
3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 188.22 (+0.79), GILD: 102.06 (+1.62), PFE: 30.67 (+0.35)
Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 102.06 (+1.62), ICPT: 163.99 (+5.89)
Studies: New Oral HCV Drug is Effective but Expensive; CBCD Reviews a Report
PRWeb - Sun Nov 16, 11:03PM CST
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 102.06 (+1.62)
Recent News posted below.
Gilead Sciences GILD other info.
http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Stock Market Today: S&P 500 Flexes Muscles After Global Markets Pop
at The Street - 12 mins ago
The S&P 500 shows some muscle on Tuesday, rocketing to a new record high as global markets rally.
URBN: 28.00 (-2.83), AGN: 211.85 (+2.65), HD: 95.67 (-2.36), ACT: 262.30 (+14.36), TERP: 33.33 (+7.49), TJX: 59.92 (-1.62), MDT: 71.77 (+2.58), GILD: 102.06 (+1.62), SUNE: 20.61 (+4.00), HIMX: 6.53 (-0.37), AAPL: 114.72 (+0.73), NOK: 7.99 (+0.32)
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - 1 hr 15 mins ago
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 102.06 (+1.62)
Early Glance: Biotechnology companies
AP - 1 hr 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 102.06 (+1.62), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - 1 hr 48 mins ago
GILD: 102.06 (+1.62)
European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - 1 hr 56 mins ago
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 102.06 (+1.62)
Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - 2 hrs 4 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 102.06 (+1.62)
Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - Tue Nov 18, 7:52AM CST
GILD: 102.06 (+1.62)
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - Tue Nov 18, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.40 (+0.15), GILD: 102.07 (+1.63), HAL: 49.10 (-0.13), AAPL: 114.72 (+0.73), BABA: 111.95 (-2.30), BHI: 65.14 (-0.09)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 102.07 (+1.63), ABBV: 65.89 (+0.85)
Final Glance: Biotechnology companies
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 102.07 (+1.63), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Gilead Sciences Earnings Hindsight: Down 10.0% in Last 20 Days (GILD)
Comtex SmarTrend(R) - Mon Nov 17, 3:00PM CST
When Gilead Sciences (NASDAQ:GILD) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.93 on sales of $6.0 billion. The company actually reported EPS of $1.84 on sales of $6.0 billion, missing EPS estimates by $0.09 and beating revenue estimates by $5.4 million. Since the company's report, shares of Gilead Sciences have fallen from $113.45 to $102.06, representing a loss of 10.0% in the past 20 days.
GILD: 102.07 (+1.63)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 109.00 (+0.70), GILD: 102.07 (+1.63), GERN: 3.09 (+0.11), MRK: 60.04 (+0.58), AZN: 73.66 (+1.16), PFE: 30.68 (+0.36), INCY: 69.60 (-0.10), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.68 (+1.30)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 109.00 (+0.70), GILD: 102.05 (+1.61), GLD: 114.77 (+0.72), ABBV: 65.89 (+0.85), TWTR: 40.23 (-0.24), NVS: 95.68 (+1.30)
Midday Glance: Biotechnology companies
AP - Mon Nov 17, 1:21PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.05 (+1.61), AMGN: 160.95 (+1.81), CELG: 106.67 (+2.31)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.26 (+2.84), GILD: 102.06 (+1.62), INCY: 69.60 (-0.10), ALXN: 190.81 (+4.03), CELG: 106.67 (+2.31)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.53 (+0.04), HAS: 56.01 (-0.36), BIIB: 305.26 (+2.84), VRTX: 110.23 (-1.39), HAL: 49.09 (-0.14), M: 61.25 (-0.36), WMT: 83.71 (+0.14), SLB: 95.46 (-0.17), COG: 33.14 (-0.39), GILD: 102.06 (+1.62), EOG: 97.14 (+0.79), ALXN: 190.81 (+4.03), MRO: 31.86 (+0.04), CSCO: 26.69 (+0.22), BHI: 65.12 (-0.11)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 109.00 (+0.70), GILD: 102.06 (+1.62), ABBV: 65.89 (+0.85), CELG: 106.67 (+2.31)
3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 188.22 (+0.79), GILD: 102.06 (+1.62), PFE: 30.67 (+0.35)
Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 102.06 (+1.62), ICPT: 163.99 (+5.89)
Studies: New Oral HCV Drug is Effective but Expensive; CBCD Reviews a Report
PRWeb - Sun Nov 16, 11:03PM CST
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 102.06 (+1.62)
